small is powerful for small molecules
High drug-load dosage forms that improve bioavailability without reliance on polymers, enabling administration of fewer, smaller tablets.
- The increased complexity of novel small molecules requires innovative drug delivery methodologies
- Nanoform’s unique particles enable high drug-loading, facilitating fewer, smaller tablets, enhanced IP protection and a high return on investment.
Review of recent small molecule FDA approvals shows that an increasing proportion of
novel molecules have increasing structural diversity, complexity and lipophilicity, making
them poorly soluble.
→Are Drugs Becoming More Lipophilic Over Time?
As a consequence, enabling technologies are needed to improve dissolution and solubility.
Using Nanoform’s innovative small molecule Nanoforming technology, Controlled
Expansion of Supercritical Solutions (CESS®), API nanoparticles can be created directly
from solution. The process can be applied successfully to up to 80% of small molecules,
and is capable of producing the world’s smallest API nanoparticles. The particles’ high
surface area drives superior dissolution rates and increased apparent solubility, without
reliance on polymers and excipients. This enables a patient centric, cost-efficient, and
green formulation, which affords stronger Intellectual Property (IP) protection for your drug.
Nanoparticles can be utilized in oral dosage forms, as injectables, ophthalmic
compositions, and as inhaled therapies.
Nanoforming delivers unique benefits to NanoImprove the
performance of your formulations:
- A reduced daily pill burden for the patient, with smaller and fewer tablets leading to
improved patient compliance and improved therapeutic effect - Improved bioavailoability without the high-loading of polymers, excipients and volatile
organic solvents associated with other solubility enhancing technologies - Technology that creates novel IP for your drug, enabling novel dosage forms that afford
enhanced protection and a high return on investment.
Get in touch to find out how our CESS® technology can help your small-molecule drugs reach their full therapeutic potential
Particle shape control
Control of morphology whilst maintaining the same polymorph
Particle size control
Particle size can be tailored depending on product performance requirements
Polymorph control
Generation of specific polymorph possible independent of nanoparticle size